Categories: News

Floraworks Says Compliant CBN Suppliers Still Need Qualified Ingredient Standards

Floraworks Distinguishes Supplier Compliance From Ingredient Qualification

Floraworks has spent the last several years evaluating cannabinol (CBN) as a mainstream food and dietary ingredient. The company says its biggest lesson was that being a compliant cannabinoid supplier and having a qualified ingredient are two very different standards.

The cannabinoid industry has historically focused heavily on manufacturing compliance, including GMPs, certificates of analysis, potency testing, contaminant testing, traceability, and state licensing. Floraworks says those systems are important and that it has invested significantly in them.

The company explains that manufacturing compliance answers the question of whether a batch passed its COA. Ingredient qualification instead asks what evidence supports the safety and identity of the ingredient for its intended use.

Floraworks says that when an ingredient is evaluated through established food and dietary supplement frameworks, manufacturing compliance is really just the starting point. The company has spent significant time evaluating CBN for both GRAS and the New Dietary Ingredient (NDI) pathway.

Floraworks says working through these frameworks requires a much more complete picture of an ingredient than the cannabinoid industry has historically had to develop.

What Floraworks Says Buyers Should Ask CBN Suppliers

Floraworks recommends separating basic supplier qualification from ingredient qualification. Buyers should verify the quality-management system, GMP status, traceability, analytical testing, specifications, and manufacturing controls.

The company says a commercial ingredient is more than the name of its principal constituent. How it is manufactured, its purity, its specifications, its impurity profile, and its consistency all matter when connecting scientific evidence to the material consumers will actually receive.

Floraworks says suppliers should be asked to define the ingredient precisely, including how it is manufactured, what controls exist around potential impurities and degradation products, and whether stability data supports the specification.

The company notes there are multiple ways to produce and purify cannabinoids. If toxicology is conducted on one material, clinical research on another, and the commercial ingredient has materially different specifications, it becomes much harder to understand what the evidence actually supports.

Floraworks says its current GRAS evaluation is built around specifically defined intended uses and exposure conditions. A safety conclusion developed around one set of conditions should not automatically be extrapolated to every other possible use.

Safety Program Findings And Next Steps

Floraworks says its safety program includes GLP toxicology work and genotoxicity evaluation. The company’s 90-day repeated-dose oral toxicology study established a no-observed-adverse-effect level (NOAEL) of 400 mg/kg body weight per day in an oral exposure model.

The company says a NOAEL has to be interpreted in the context of the study design, the test material, intended human exposure, the broader peer-reviewed scientific literature, and other available safety information. It advises against viewing a single number as the safety story.

Floraworks says working through a formal safety assessment demonstrates what the evidence supports, where it is limited, and where additional testing may be warranted. The customer-focused question shaping its research program is what additional research needs to be performed to better inform the consumer.

Related Stories

Friday

Friday is a San Diego based writer covering cannabis news, culture, and business. Known for sharp analysis and clean reporting, Friday helps readers navigate the industry without the fluff. Every article is built on research, real sources, and a deep commitment to the cannabis community.

Recent Posts

Texas Cannabis Policy Center Sees Path Forward As Legalization Hurdles Remain

A New Day in Texas Sarah Todd, director of the Texas Cannabis Policy Center, said she felt optimism for an…

40 minutes ago

Newfoundland and Labrador Proposes Cannabis Control Act Changes After Five-Year Review

Amendments Follow Five-Year Review The Provincial Government has introduced amendments to the Cannabis Control Act in Newfoundland and Labrador. The…

4 hours ago

Chula Vista Rejects Cannabis Permit Applicant Who Claims City Ignored Its Own Rules

Rejected Applicant Takes Chula Vista to Court Laura Wilkinson Sinton, a small business owner from Coronado, applied to open a…

13 hours ago

College Station Medical Cannabis Dispensary To Replace Former Ozona Grill Site

Trulieve Plans Dispensary At Former Ozona Grill Site A medical cannabis dispensary is set to take over the former Ozona…

15 hours ago

TribeTokes CBD Plus CBN Sleep Gummies Top THC-Free Sleep Product Rankings

TribeTokes Tops THC-Free Sleep Gummy Rankings A product review has named the TribeTokes CBD + CBN Sleep Gummy the best…

19 hours ago

Alice O’Leary Randall Preserves Medical Marijuana Movement History 50 Years On

A Pioneer Preserves a Movement's Origins Fifty years after her late husband became the first American in modern times to…

22 hours ago

NUG Magazine is published and distributed by NUG Magazine LLC. Established in 2009,
We have been bringing you the latest and up to date information from the cannabis market.
All contents are for entertainment and educational purposes only and are intended for mature audiences.

Products

Search Nug Magazine!

Advertisement

Instagram @Nugmagazine

[instagram-feed]

About NUG

We are the #1 Source for your Cannabis news and information